Keyhole limpet hemocyanin potentiates standard immunotherapy for melanoma

American Journal of Surgery

Volumn 193, Issue 2, 2007, Pages 284-287

  McFadden, David W ^a   Riggs, Dale R ^a   Jackson, Barbara J ^a   Ng, Alex ^a   Cunningham, Cynthia ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cytokines; Growth inhibition; Keyhole limpet hemocyanin; Melanoma; Vascular endothelial growth factor

Indexed keywords

KEYHOLE LIMPET HEMOCYANIN; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SYNERGISM; HEMOCYANIN; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; MELANOMA; SKIN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33846218547     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2006.09.009     Document Type: Article

References (24)

1. Jemal A., Siegal R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. McGillis S.T., and Fein H. Topical treatment strategies for non-melanoma skin cancer and precursor lesions. Semin Cutan Med Surg 23 (2004) 174-183
3. Villa A.M., and Berman B. Immunomodulators for skin cancer. J Drugs Dermatol 3 (2004) 533-539
4. Harris J.R., and Markl J. Keyhole limpet hemocyanin: molecular structure of a potent marine immunoactivator. A review. Eur Urol 37 Suppl 3 (2000) 24-33
5. Tzianabos A.O. Polysaccharide immunomodulators as therapeutic agents: structural aspects and biologic function. Clin Microbiol Rev 13 (2000) 523-533
6. Olsson C.A., Chute R., and Rao C.N. Immunologic reduction of bladder cancer recurrence rate. J Urol 111 (1974) 173-176
7. Riggs D.R., Tarry W.F., DeHaven J.I., et al. Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy. J Urol 147 (1992) 212-214
8. Jurincic C.D., Engelmann U., Gasch J., and Klippel K.F. Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study. J Urol 139 (1988) 723-726
9. Jurincic-Winkler C.D., Metz K.A., Beuth J., and Klippel K.F. Keyhole limpet hemocyanin for carcinoma in situ of the bladder: a long-term follow-up study. Eur Urol 37 Suppl 3 (2000) 45-49
10. Lamm D.L., DeHaven J.I., and Riggs D.R. Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies. Eur Urol 37 Suppl 3 (2000) 41-44
11. Riggs D., Jackson B., Vona-Davis L., and McFadden D. In vitro anticancer effects of a novel immunostimulant: keyhole limpet hemocyanin. J Surg Res 108 (2002) 279-284
12. Somasundar P., Riggs D.R., Jackson B.J., and McFadden D.W. Inhibition of melanoma growth by hemocyanin occurs via early apoptotic pathways. Am J Surg 190 (2005) 713-716
13. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
14. th ed. (1983), McGraw-Hill, New York
15. Ludbrook J. Multiple comparison procedures updated. Clin Exp Pharmacol Physiol 25 (1998) 1032-1037
16. Veronesi U., Cascinelli N., Adamus J., et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med 18 (1988) 1159-1162
17. Wagner J.D., Gordon M.S., Chuang T.Y., et al. Current therapy of cutaneous melanoma. Plast Reconstr Surg 105 (2000) 1774-1799 quiz 1800-1
18. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14 (1996) 7-17
19. Kirkwood J.M., Ibrahim J., Lawson D.H., et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol 19 (2001) 1430-1436
20. Atkins M.B., Lotze M.T., Dutcher J.P., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17 (1999) 2105-2116
21. Riggs D.R., Jackson B.J., Vona-Davis L., et al. A novel immunostimulant, keyhole limphet hemocyanin, inhibits human cancer growth and alters cytokine production in vitro. Am J Surg 189 (2005) 680-684
22. McFadden D.W., Riggs D.R., Jackson B.J., and Vona-Davis L. Keyhole limpet hemocyanin, a novel immune stimulant with promising anticancer activity in Barrett's esophageal adenocarcinoma. Am J Surg 186 (2003) 552-555
23. Vona-Davis L., Vincent T., Zulfigar S., et al. Proteomic analysis of SEG-1 human Barrett's-associated esophageal adenocarcinoma cells treated with keyhole limpet hemocyanin. J Gast Surg 8 (2004) 1018-1023
24. Rizvi I., Riggs D.R., Jackson B.J., et al. Inositol hexaphosphate (IP6) inhibits cellular proliferation in melanoma. J Surg Res 133 (2006) 3-6